

Contents

Appendix A:.....	2
Supplementary Table 1	2
Supplementary Table 2	2
Supplementary Table 3	3
Supplementary Table 4	3
Supplementary Table 5	4
Supplementary Table 6	4

Appendix A:**Supplementary Table 1.** Classification of the primary outcome (n=134 registered trials with prespecified primary outcome)

Primary outcome classification	n (%)
Statistically positive	74 (55.2)
Nonstatistically positive	9 (6.7)
Neutral	31 (23.1)
Nonstatistically negative	5 (3.7)
Statistically negative	1 (0.7)
Indeterminate	11 (8.2)
Noncomparative	3 (2.2)

Supplementary Table 2. Type of change in primary outcome (n=134 registered trials with prespecified primary outcome)

Type of change in primary outcome	n (%)
No change	115 (85.8)
Change in definition or measure	6 (4.5)
Added	5 (3.7)
Upgrade	4 (3.0)
Omitted	3 (2.2)
Downgrade	1 (0.7)

Supplementary Table 3. Reviewer's interpretation of the study conclusion (n=203 trial publications)

Conclusions	n (%)
Positive	161 (79.3)
Neutral	26 (12.8)
Negative	1 (0.5)
Indeterminate	10 (4.9)
Noncomparative	5 (2.5)

Supplementary Table 4. Characteristics of SAE outcome discrepancies. Indicates the difference in SAE reporting between publication and trial registry, including the type of change and number of inconsistent events in each category

Type of SAE change	Number of studies	Number of discrepant events across the 14 trials			
		Intervention arm		Control arm	
		n	Median (IQR)	n	Median (IQR)
SAEs not reported in publication	7	233	7 (5.5–15.5)	74	3 (1.5–10)
Fewer SAEs in publication	4	128	8.5 (1.5–39)	2	0 (0–0.5)
More SAEs in publication	3	11	4 (3–4.5)	4	0 (0–2)
	Total	372		80	

*Abbreviations: IQR, interquartile range; SAE, serious adverse effects

Supplementary Table 5. Mean ranks and surface under the cumulative ranking curve (SUCRA) values of the AD NMA treatment groups with and without additional trial registry SAEs

Treatment groups	Without registry SAE data		With registry SAE data	
	SUCRA	Mean rank	SUCRA	Mean rank
Rivastigmine Patch	72.4	3.2	72.7	3.2
Donepezil+Memantine	71	3.3	69.3	3.5
Rivastigmine Patch+Memantine	64.1	3.9	64.7	3.8
Galantamine	56.3	4.5	55.8	4.5
Memantine	52	4.8	51.4	4.9
Placebo	41.4	5.7	41.8	5.7
Donepezil	39.2	5.9	38.8	5.9
Galantamine+Memantine	32.7	6.4	34	6.3
Rivastigmine PO	21.1	7.3	21.4	7.3

*Abbreviations: PO, oral route

Supplementary Table 6. Mean ranks and surface under the cumulative ranking curve (SUCRA) values of the AD NMA treatment groups by registration status

Treatment	All randomized trials		Registered randomized trials		Non-registered randomized trials	
	SUCRA	Mean rank	SUCRA	Mean rank	SUCRA	Mean rank
Placebo	44.8	5.4	33.7	6.3	63.7	2.5
Donepezil	35.8	6.1	39.4	5.8	33.1	3.7
Rivastigmine PO	21.2	7.3	66.1	3.7	32.2	3.7
Galantamine	42.6	5.6	29.2	6.7	90.9	1.4
Rivastigmine Patch	77.3	2.8	61.9	4	NA	NA
Memantine	55.5	4.6	63	4	30.1	3.8
Galantamine+Memantine	35.7	6.1	27.5	6.8	NA	NA
Rivastigmine Patch+Memantine	65.8	3.7	57.7	4.4	NA	NA
Donepezil+Memantine	71.2	3.3	71.6	3.3	NA	NA

*Abbreviations: PO, oral route